Análisis de ratios de rentabilidad
Datos trimestrales
Los ratios de rentabilidad miden la capacidad de la empresa para generar ventas rentables a partir de sus recursos (activos).
Ratios de rentabilidad (resumen)
Eli Lilly & Co., ratios de rentabilidad (datos trimestrales)
Basado en los informes: 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31), 10-K (Fecha del informe: 2019-12-31), 10-Q (Fecha del informe: 2019-09-30), 10-Q (Fecha del informe: 2019-06-30), 10-Q (Fecha del informe: 2019-03-31).
| Ratio de rentabilidad | Descripción | La empresa |
|---|---|---|
| Ratio de margen de beneficio bruto | El índice de margen de beneficio bruto indica el porcentaje de los ingresos disponibles para cubrir los gastos operativos y de otro tipo. | El ratio de margen de beneficio bruto de Eli Lilly & Co. mejorado del 1T 2024 al 2T 2024 y del 2T 2024 al 3T 2024. |
| Ratio de margen de beneficio operativo | Ratio de rentabilidad calculado como el resultado de explotación dividido por los ingresos. | El ratio de margen de beneficio operativo de Eli Lilly & Co. mejorado del 1T 2024 al Q2 2024 y del Q2 2024 al Q3 2024. |
| Ratio de margen de beneficio neto | Un indicador de rentabilidad, calculado como el ingreso neto dividido por los ingresos. | El ratio de margen de beneficio neto de Eli Lilly & Co. mejorado del 1T 2024 al Q2 2024 y del Q2 2024 al Q3 2024. |
| Ratio de rentabilidad | Descripción | La empresa |
|---|---|---|
| ROE | Ratio de rentabilidad calculado como el beneficio neto dividido por el patrimonio neto. | El ratio de rentabilidad sobre el capital contable de Eli Lilly & Co. mejorado del 1T 2024 al 2T 2024 y del 2T 2024 al 3T 2024. |
| ROA | Ratio de rentabilidad calculado como el ingreso neto dividido por los activos totales. | El ratio de rentabilidad sobre activos de Eli Lilly & Co. mejorado del 1T 2024 al Q2 2024 y del Q2 2024 al Q3 2024. |
Ratio de margen de beneficio bruto
Eli Lilly & Co., ratio de margen de beneficio bruto, cálculo (datos trimestrales)
| 30 sept. 2024 | 30 jun. 2024 | 31 mar. 2024 | 31 dic. 2023 | 30 sept. 2023 | 30 jun. 2023 | 31 mar. 2023 | 31 dic. 2022 | 30 sept. 2022 | 30 jun. 2022 | 31 mar. 2022 | 31 dic. 2021 | 30 sept. 2021 | 30 jun. 2021 | 31 mar. 2021 | 31 dic. 2020 | 30 sept. 2020 | 30 jun. 2020 | 31 mar. 2020 | 31 dic. 2019 | 30 sept. 2019 | 30 jun. 2019 | 31 mar. 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Datos financieros seleccionados (US$ en miles) | ||||||||||||||||||||||||||||||
| Margen bruto | 9,268,300) | 9,132,600) | 7,094,500) | 7,565,400) | 7,638,500) | 6,504,700) | 5,333,300) | 5,753,700) | 5,362,500) | 5,057,500) | 5,737,900) | 5,949,700) | 5,342,000) | 4,786,900) | 4,927,000) | 5,720,200) | 4,414,200) | 4,277,400) | 4,644,700) | 4,831,400) | 4,301,600) | 4,511,800) | 3,953,500) | |||||||
| Ingresos | 11,439,100) | 11,302,800) | 8,768,000) | 9,353,400) | 9,498,600) | 8,312,100) | 6,960,000) | 7,301,800) | 6,941,600) | 6,488,000) | 7,810,000) | 7,999,900) | 6,772,800) | 6,740,100) | 6,805,600) | 7,440,000) | 5,740,600) | 5,499,400) | 5,859,800) | 6,114,000) | 5,476,600) | 5,636,700) | 5,092,200) | |||||||
| Ratio de rentabilidad | ||||||||||||||||||||||||||||||
| Ratio de margen de beneficio bruto1 | 80.91% | 80.75% | 80.16% | 79.25% | 78.67% | 77.77% | 77.67% | 76.77% | 75.61% | 75.98% | 74.40% | 74.18% | 74.85% | 74.27% | 75.88% | 77.66% | 78.26% | 78.67% | 79.22% | 78.85% | — | — | — | |||||||
| Referencia | ||||||||||||||||||||||||||||||
| Ratio de margen de beneficio brutoCompetidores2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 67.21% | 62.75% | 62.28% | 62.42% | 65.76% | 68.91% | 69.43% | 70.00% | 69.62% | 70.48% | 69.53% | 68.96% | 67.72% | 65.62% | 64.82% | 66.41% | 68.74% | 73.56% | 77.43% | 77.64% | — | — | — | |||||||
| Amgen Inc. | 58.71% | 61.56% | 64.76% | 68.60% | 72.35% | 72.87% | 73.65% | 74.17% | 73.99% | 74.00% | 73.30% | 73.44% | 74.00% | 73.97% | 74.37% | 74.59% | 75.55% | 77.15% | 78.90% | 80.38% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 74.91% | 75.38% | 75.71% | 76.24% | 76.54% | 77.01% | 77.68% | 78.04% | 78.82% | 79.13% | 79.62% | 78.57% | 76.92% | 75.88% | 74.42% | 72.31% | 71.18% | 69.47% | 68.02% | 69.10% | — | — | — | |||||||
| Danaher Corp. | 59.37% | 59.27% | 58.39% | 58.74% | 58.77% | 59.17% | 60.22% | 60.21% | 60.65% | 60.77% | 60.77% | 60.95% | 60.44% | 59.24% | 57.60% | 55.98% | 55.04% | 55.28% | 55.85% | 55.74% | — | — | — | |||||||
| Gilead Sciences Inc. | 75.98% | 75.56% | 75.62% | 75.87% | 78.66% | 79.27% | 78.94% | 79.03% | 74.31% | 75.30% | 75.50% | 75.56% | 80.23% | 79.90% | 80.32% | 81.23% | 78.72% | 78.25% | 79.06% | 78.86% | — | — | — | |||||||
| Johnson & Johnson | 69.05% | 69.06% | 69.20% | 68.82% | 68.54% | 68.06% | 67.34% | 67.26% | 67.43% | 67.86% | 67.97% | 68.16% | 67.51% | 67.00% | 66.24% | 65.58% | 65.68% | 65.66% | 66.15% | 66.42% | — | — | — | |||||||
| Merck & Co. Inc. | 75.82% | 75.25% | 74.37% | 73.17% | 72.86% | 72.96% | 72.43% | 70.63% | 70.49% | 70.41% | 70.72% | 72.02% | 67.95% | 67.48% | 66.99% | 67.74% | 71.23% | 70.06% | 70.11% | 69.87% | — | — | — | |||||||
| Moderna Inc. | 66.68% | 31.01% | 20.22% | 29.65% | 34.97% | 55.04% | 63.80% | 70.62% | 78.30% | 81.66% | 84.26% | 85.19% | 84.71% | 84.49% | 89.60% | 96.03% | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 67.73% | 58.18% | 58.09% | 58.10% | 60.97% | 69.61% | 68.61% | 65.77% | 65.53% | 62.18% | 60.35% | 62.08% | 65.28% | 70.96% | 76.46% | 79.26% | 80.47% | 80.19% | 80.03% | 80.25% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 86.12% | 86.16% | 86.32% | 86.16% | 85.96% | 86.42% | 86.96% | 87.18% | 85.39% | 84.97% | 84.65% | 84.83% | 86.65% | 86.85% | 86.84% | 86.82% | 87.98% | 88.21% | 89.72% | 90.05% | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 40.77% | 40.76% | 40.40% | 39.90% | 39.87% | 39.75% | 40.28% | 42.24% | 44.42% | 46.63% | 48.37% | 50.08% | 51.05% | 51.29% | 51.47% | 49.67% | 47.31% | 45.39% | 44.30% | 44.35% | — | — | — | |||||||
Basado en los informes: 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31), 10-K (Fecha del informe: 2019-12-31), 10-Q (Fecha del informe: 2019-09-30), 10-Q (Fecha del informe: 2019-06-30), 10-Q (Fecha del informe: 2019-03-31).
1 Q3 2024 cálculo
Ratio de margen de beneficio bruto = 100
× (Margen brutoQ3 2024
+ Margen brutoQ2 2024
+ Margen brutoQ1 2024
+ Margen brutoQ4 2023)
÷ (IngresosQ3 2024
+ IngresosQ2 2024
+ IngresosQ1 2024
+ IngresosQ4 2023)
= 100 × (9,268,300 + 9,132,600 + 7,094,500 + 7,565,400)
÷ (11,439,100 + 11,302,800 + 8,768,000 + 9,353,400)
= 80.91%
2 Haga clic en el nombre del competidor para ver los cálculos.
| Ratio de rentabilidad | Descripción | La empresa |
|---|---|---|
| Ratio de margen de beneficio bruto | El índice de margen de beneficio bruto indica el porcentaje de los ingresos disponibles para cubrir los gastos operativos y de otro tipo. | El ratio de margen de beneficio bruto de Eli Lilly & Co. mejorado del 1T 2024 al 2T 2024 y del 2T 2024 al 3T 2024. |
Ratio de margen de beneficio operativo
Eli Lilly & Co., ratio de margen de beneficio operativo, cálculo (datos trimestrales)
| 30 sept. 2024 | 30 jun. 2024 | 31 mar. 2024 | 31 dic. 2023 | 30 sept. 2023 | 30 jun. 2023 | 31 mar. 2023 | 31 dic. 2022 | 30 sept. 2022 | 30 jun. 2022 | 31 mar. 2022 | 31 dic. 2021 | 30 sept. 2021 | 30 jun. 2021 | 31 mar. 2021 | 31 dic. 2020 | 30 sept. 2020 | 30 jun. 2020 | 31 mar. 2020 | 31 dic. 2019 | 30 sept. 2019 | 30 jun. 2019 | 31 mar. 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Datos financieros seleccionados (US$ en miles) | ||||||||||||||||||||||||||||||
| Resultado de explotación | 1,526,400) | 3,714,800) | 2,509,000) | 2,387,800) | 450,400) | 2,125,700) | 1,494,000) | 1,836,400) | 1,676,500) | 1,210,100) | 2,404,300) | 1,917,200) | 1,881,200) | 1,403,400) | 1,155,300) | 1,992,100) | 1,278,300) | 1,196,800) | 1,590,800) | 1,400,200) | 1,430,700) | 1,498,300) | 645,100) | |||||||
| Ingresos | 11,439,100) | 11,302,800) | 8,768,000) | 9,353,400) | 9,498,600) | 8,312,100) | 6,960,000) | 7,301,800) | 6,941,600) | 6,488,000) | 7,810,000) | 7,999,900) | 6,772,800) | 6,740,100) | 6,805,600) | 7,440,000) | 5,740,600) | 5,499,400) | 5,859,800) | 6,114,000) | 5,476,600) | 5,636,700) | 5,092,200) | |||||||
| Ratio de rentabilidad | ||||||||||||||||||||||||||||||
| Ratio de margen de beneficio operativo1 | 24.81% | 23.28% | 20.80% | 18.92% | 18.42% | 24.17% | 22.45% | 24.97% | 24.65% | 25.50% | 25.94% | 22.45% | 23.17% | 21.81% | 22.06% | 24.69% | 23.55% | 24.48% | 25.64% | 22.29% | — | — | — | |||||||
| Referencia | ||||||||||||||||||||||||||||||
| Ratio de margen de beneficio operativoCompetidores2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 24.89% | 22.31% | 23.50% | 23.49% | 27.32% | 31.03% | 28.49% | 31.21% | 30.59% | 30.33% | 32.68% | 31.89% | 30.09% | 28.95% | 23.63% | 24.81% | 28.45% | 30.17% | 39.86% | 39.03% | — | — | — | |||||||
| Amgen Inc. | 19.97% | 20.96% | 24.72% | 29.35% | 34.55% | 37.50% | 36.07% | 38.57% | 39.31% | 38.04% | 32.78% | 31.44% | 30.14% | 30.72% | 37.23% | 37.70% | 38.59% | 39.76% | 41.89% | 43.57% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -14.05% | -14.39% | -14.30% | 16.18% | 16.96% | 17.29% | 18.13% | 17.96% | 19.04% | 18.19% | 16.79% | 15.91% | -15.73% | -17.02% | -19.19% | -21.60% | 9.27% | 11.67% | 16.30% | 22.62% | — | — | — | |||||||
| Danaher Corp. | 20.11% | 21.22% | 21.05% | 21.77% | 23.83% | 25.06% | 27.02% | 27.61% | 27.35% | 25.44% | 25.23% | 25.35% | 24.63% | 25.04% | 22.30% | 18.99% | 17.61% | 17.37% | 18.01% | 18.25% | — | — | — | |||||||
| Gilead Sciences Inc. | 2.92% | 9.26% | 5.79% | 28.24% | 30.37% | 31.18% | 33.03% | 27.17% | 22.39% | 25.78% | 26.56% | 36.72% | 42.79% | 37.20% | 18.07% | 16.72% | 11.01% | -4.40% | 19.89% | 19.38% | — | — | — | |||||||
| Johnson & Johnson | 24.42% | 25.31% | 25.04% | 24.90% | 25.55% | 25.61% | 25.21% | 24.63% | 23.89% | 23.47% | 23.76% | 24.95% | 24.69% | 25.23% | 24.10% | 23.60% | 24.30% | 24.64% | 25.62% | 24.15% | — | — | — | |||||||
| Merck & Co. Inc. | 21.60% | 24.75% | 6.93% | 3.92% | 13.08% | 10.34% | 27.85% | 30.27% | 30.66% | 33.04% | 28.85% | 25.74% | 14.07% | 10.64% | 14.02% | 16.47% | 26.87% | 25.40% | 25.49% | 24.77% | — | — | — | |||||||
| Moderna Inc. | -54.25% | -94.57% | -102.57% | -63.54% | -30.50% | 5.08% | 33.67% | 51.10% | 64.60% | 70.46% | 74.34% | 75.22% | 69.57% | 62.28% | 32.79% | -381.82% | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 9.56% | -4.19% | -2.08% | 2.15% | 14.36% | 28.13% | 34.44% | 34.83% | 33.59% | 30.37% | 26.12% | 23.91% | 24.67% | 24.12% | 21.20% | 19.47% | 21.17% | 21.17% | 24.20% | 25.46% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 28.69% | 28.95% | 29.40% | 30.85% | 32.23% | 34.20% | 35.79% | 38.93% | 45.45% | 48.19% | 55.08% | 55.67% | 55.19% | 53.94% | 43.37% | 42.09% | 37.43% | 34.64% | 30.45% | 28.10% | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 16.93% | 17.01% | 16.38% | 16.00% | 15.81% | 15.42% | 16.29% | 18.69% | 20.54% | 22.51% | 23.83% | 25.57% | 27.04% | 28.00% | 27.68% | 24.19% | 20.90% | 17.05% | 17.86% | 17.99% | — | — | — | |||||||
Basado en los informes: 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31), 10-K (Fecha del informe: 2019-12-31), 10-Q (Fecha del informe: 2019-09-30), 10-Q (Fecha del informe: 2019-06-30), 10-Q (Fecha del informe: 2019-03-31).
1 Q3 2024 cálculo
Ratio de margen de beneficio operativo = 100
× (Resultado de explotaciónQ3 2024
+ Resultado de explotaciónQ2 2024
+ Resultado de explotaciónQ1 2024
+ Resultado de explotaciónQ4 2023)
÷ (IngresosQ3 2024
+ IngresosQ2 2024
+ IngresosQ1 2024
+ IngresosQ4 2023)
= 100 × (1,526,400 + 3,714,800 + 2,509,000 + 2,387,800)
÷ (11,439,100 + 11,302,800 + 8,768,000 + 9,353,400)
= 24.81%
2 Haga clic en el nombre del competidor para ver los cálculos.
| Ratio de rentabilidad | Descripción | La empresa |
|---|---|---|
| Ratio de margen de beneficio operativo | Ratio de rentabilidad calculado como el resultado de explotación dividido por los ingresos. | El ratio de margen de beneficio operativo de Eli Lilly & Co. mejorado del 1T 2024 al Q2 2024 y del Q2 2024 al Q3 2024. |
Ratio de margen de beneficio neto
Eli Lilly & Co., ratio de margen de beneficio neto, cálculo (datos trimestrales)
| 30 sept. 2024 | 30 jun. 2024 | 31 mar. 2024 | 31 dic. 2023 | 30 sept. 2023 | 30 jun. 2023 | 31 mar. 2023 | 31 dic. 2022 | 30 sept. 2022 | 30 jun. 2022 | 31 mar. 2022 | 31 dic. 2021 | 30 sept. 2021 | 30 jun. 2021 | 31 mar. 2021 | 31 dic. 2020 | 30 sept. 2020 | 30 jun. 2020 | 31 mar. 2020 | 31 dic. 2019 | 30 sept. 2019 | 30 jun. 2019 | 31 mar. 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Datos financieros seleccionados (US$ en miles) | ||||||||||||||||||||||||||||||
| Utilidad (pérdida) neta | 970,300) | 2,967,000) | 2,242,900) | 2,189,700) | (57,400) | 1,763,200) | 1,344,900) | 1,937,700) | 1,451,700) | 952,500) | 1,902,900) | 1,726,100) | 1,110,100) | 1,390,200) | 1,355,300) | 2,116,800) | 1,208,400) | 1,412,000) | 1,456,500) | 1,495,700) | 1,253,900) | 1,327,200) | 4,241,600) | |||||||
| Ingresos | 11,439,100) | 11,302,800) | 8,768,000) | 9,353,400) | 9,498,600) | 8,312,100) | 6,960,000) | 7,301,800) | 6,941,600) | 6,488,000) | 7,810,000) | 7,999,900) | 6,772,800) | 6,740,100) | 6,805,600) | 7,440,000) | 5,740,600) | 5,499,400) | 5,859,800) | 6,114,000) | 5,476,600) | 5,636,700) | 5,092,200) | |||||||
| Ratio de rentabilidad | ||||||||||||||||||||||||||||||
| Ratio de margen de beneficio neto1 | 20.48% | 18.86% | 17.08% | 15.36% | 15.55% | 22.01% | 20.54% | 21.88% | 20.63% | 19.58% | 20.90% | 19.71% | 21.52% | 22.71% | 23.91% | 25.24% | 24.01% | 24.48% | 23.97% | 37.27% | — | — | — | |||||||
| Referencia | ||||||||||||||||||||||||||||||
| Ratio de margen de beneficio netoCompetidores2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 9.22% | 9.71% | 11.02% | 8.95% | 11.81% | 15.50% | 13.37% | 20.39% | 23.19% | 22.04% | 22.00% | 20.54% | 13.66% | 12.40% | 10.28% | 10.08% | 18.16% | 19.20% | 24.77% | 23.69% | — | — | — | |||||||
| Amgen Inc. | 13.58% | 10.60% | 13.35% | 24.96% | 29.52% | 31.52% | 31.77% | 26.42% | 27.88% | 26.73% | 23.42% | 24.25% | 23.03% | 23.80% | 29.60% | 29.97% | 30.91% | 31.53% | 33.64% | 35.32% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -15.30% | -14.06% | -13.50% | 17.83% | 18.44% | 17.62% | 15.95% | 13.71% | 14.29% | 14.04% | 13.31% | 15.08% | -11.89% | -11.44% | -14.53% | -21.20% | -0.11% | -1.61% | 3.08% | 13.15% | — | — | — | |||||||
| Danaher Corp. | 16.39% | 17.83% | 18.54% | 19.94% | 22.89% | 22.80% | 23.32% | 22.91% | 21.65% | 20.61% | 21.32% | 21.84% | 20.97% | 21.00% | 19.17% | 16.36% | 18.05% | 18.35% | 18.13% | 16.80% | — | — | — | |||||||
| Gilead Sciences Inc. | 0.45% | 3.82% | 1.78% | 21.03% | 21.60% | 20.18% | 20.87% | 17.02% | 12.44% | 15.22% | 16.60% | 23.05% | 27.21% | 19.62% | 1.19% | 0.51% | 5.56% | -1.18% | 22.17% | 24.35% | — | — | — | |||||||
| Johnson & Johnson | 16.74% | 43.91% | 44.92% | 41.28% | 39.58% | 14.52% | 13.77% | 18.90% | 19.95% | 19.21% | 20.90% | 22.26% | 19.55% | 19.92% | 17.95% | 17.82% | 21.01% | 18.86% | 20.75% | 18.42% | — | — | — | |||||||
| Merck & Co. Inc. | 19.23% | 21.98% | 3.76% | 0.61% | 7.77% | 5.34% | 22.52% | 24.49% | 25.88% | 29.00% | 26.27% | 26.79% | 15.09% | 11.83% | 15.09% | 14.72% | 24.33% | 22.20% | 21.10% | 21.01% | — | — | — | |||||||
| Moderna Inc. | -44.80% | -119.71% | -119.12% | -70.66% | -39.67% | 11.95% | 33.37% | 45.36% | 57.36% | 63.31% | 66.94% | 69.04% | 64.55% | 57.01% | 30.95% | -373.77% | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 7.04% | -4.62% | -0.55% | 3.56% | 15.13% | 27.38% | 31.19% | 31.27% | 29.81% | 28.94% | 27.01% | 27.04% | 28.77% | 23.86% | 24.03% | 22.95% | 18.59% | 31.31% | 32.32% | 31.45% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 33.61% | 32.04% | 29.45% | 30.14% | 30.47% | 33.93% | 33.81% | 35.64% | 39.17% | 39.97% | 48.06% | 50.25% | 51.65% | 50.11% | 43.53% | 41.35% | 38.28% | 37.30% | 28.56% | 26.91% | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 14.48% | 14.69% | 14.20% | 13.99% | 13.68% | 13.14% | 13.75% | 15.47% | 15.92% | 17.37% | 18.49% | 19.70% | 21.93% | 22.47% | 22.08% | 19.79% | 17.12% | 14.12% | 14.31% | 14.47% | — | — | — | |||||||
Basado en los informes: 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31), 10-K (Fecha del informe: 2019-12-31), 10-Q (Fecha del informe: 2019-09-30), 10-Q (Fecha del informe: 2019-06-30), 10-Q (Fecha del informe: 2019-03-31).
1 Q3 2024 cálculo
Ratio de margen de beneficio neto = 100
× (Utilidad (pérdida) netaQ3 2024
+ Utilidad (pérdida) netaQ2 2024
+ Utilidad (pérdida) netaQ1 2024
+ Utilidad (pérdida) netaQ4 2023)
÷ (IngresosQ3 2024
+ IngresosQ2 2024
+ IngresosQ1 2024
+ IngresosQ4 2023)
= 100 × (970,300 + 2,967,000 + 2,242,900 + 2,189,700)
÷ (11,439,100 + 11,302,800 + 8,768,000 + 9,353,400)
= 20.48%
2 Haga clic en el nombre del competidor para ver los cálculos.
| Ratio de rentabilidad | Descripción | La empresa |
|---|---|---|
| Ratio de margen de beneficio neto | Un indicador de rentabilidad, calculado como el ingreso neto dividido por los ingresos. | El ratio de margen de beneficio neto de Eli Lilly & Co. mejorado del 1T 2024 al Q2 2024 y del Q2 2024 al Q3 2024. |
Ratio de rendimiento sobre el capital contable (ROE)
Eli Lilly & Co., ROE, cálculo (datos trimestrales)
| 30 sept. 2024 | 30 jun. 2024 | 31 mar. 2024 | 31 dic. 2023 | 30 sept. 2023 | 30 jun. 2023 | 31 mar. 2023 | 31 dic. 2022 | 30 sept. 2022 | 30 jun. 2022 | 31 mar. 2022 | 31 dic. 2021 | 30 sept. 2021 | 30 jun. 2021 | 31 mar. 2021 | 31 dic. 2020 | 30 sept. 2020 | 30 jun. 2020 | 31 mar. 2020 | 31 dic. 2019 | 30 sept. 2019 | 30 jun. 2019 | 31 mar. 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Datos financieros seleccionados (US$ en miles) | ||||||||||||||||||||||||||||||
| Utilidad (pérdida) neta | 970,300) | 2,967,000) | 2,242,900) | 2,189,700) | (57,400) | 1,763,200) | 1,344,900) | 1,937,700) | 1,451,700) | 952,500) | 1,902,900) | 1,726,100) | 1,110,100) | 1,390,200) | 1,355,300) | 2,116,800) | 1,208,400) | 1,412,000) | 1,456,500) | 1,495,700) | 1,253,900) | 1,327,200) | 4,241,600) | |||||||
| Capital social total de Eli Lilly and Company | 14,240,000) | 13,562,000) | 12,812,200) | 10,771,900) | 11,220,400) | 11,063,800) | 11,190,400) | 10,649,800) | 10,070,100) | 8,544,700) | 9,330,800) | 8,979,200) | 7,757,000) | 6,444,400) | 6,898,700) | 5,641,600) | 4,826,900) | 4,092,900) | 3,078,800) | 2,606,900) | 3,382,500) | 2,780,500) | 2,480,300) | |||||||
| Ratio de rentabilidad | ||||||||||||||||||||||||||||||
| ROE1 | 58.78% | 54.14% | 47.91% | 48.65% | 44.46% | 58.73% | 50.82% | 58.64% | 59.91% | 66.61% | 65.69% | 62.16% | 76.99% | 94.20% | 88.31% | 109.79% | 115.45% | 137.26% | 179.72% | 319.09% | — | — | — | |||||||
| Referencia | ||||||||||||||||||||||||||||||
| ROECompetidores2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 84.91% | 78.77% | 74.85% | 46.94% | 53.86% | 67.50% | 57.14% | 68.60% | 83.83% | 86.24% | 76.64% | 74.91% | 55.60% | 53.01% | 37.63% | 35.30% | 48.34% | 47.30% | — | — | — | — | — | |||||||
| Amgen Inc. | 56.20% | 52.83% | 74.93% | 107.78% | 98.82% | 117.67% | 148.04% | 178.97% | 187.11% | 271.85% | 624.78% | 87.96% | 68.26% | 69.67% | 75.91% | 77.20% | 67.09% | 68.48% | 80.92% | 81.07% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -42.34% | -38.44% | -37.28% | 27.27% | 28.57% | 24.91% | 22.97% | 20.37% | 20.44% | 20.30% | 19.79% | 19.46% | -14.52% | -13.80% | -16.54% | -23.84% | -0.09% | -1.15% | 1.91% | 6.66% | — | — | — | |||||||
| Danaher Corp. | 7.59% | 8.42% | 8.24% | 8.91% | 11.29% | 12.30% | 13.47% | 14.39% | 14.40% | 13.63% | 13.93% | 14.24% | 13.54% | 13.12% | 11.76% | 9.17% | 9.70% | 9.56% | 10.53% | 9.94% | — | — | — | |||||||
| Gilead Sciences Inc. | 0.69% | 5.77% | 2.77% | 24.81% | 26.33% | 25.92% | 26.59% | 21.62% | 15.82% | 20.44% | 22.66% | 29.55% | 34.44% | 26.20% | 1.59% | 0.68% | 7.27% | -1.43% | 22.49% | 23.91% | — | — | — | |||||||
| Johnson & Johnson | 20.93% | 53.14% | 54.95% | 51.11% | 48.61% | 17.37% | 17.95% | 23.36% | 25.68% | 24.05% | 26.54% | 28.20% | 25.44% | 25.53% | 22.96% | 23.25% | 26.35% | 24.11% | 28.01% | 25.42% | — | — | — | |||||||
| Merck & Co. Inc. | 27.30% | 31.52% | 5.71% | 0.97% | 11.17% | 8.04% | 27.82% | 31.57% | 34.32% | 38.34% | 34.68% | 34.17% | 20.10% | 16.73% | 26.08% | 27.91% | 39.47% | 37.91% | 38.72% | 37.99% | — | — | — | |||||||
| Moderna Inc. | -18.65% | -50.09% | -46.56% | -34.03% | -25.76% | 7.12% | 25.36% | 43.73% | 65.39% | 78.15% | 85.73% | 86.26% | 69.75% | 52.13% | 15.59% | -29.17% | -21.66% | -16.54% | -30.82% | -43.75% | — | — | — | |||||||
| Pfizer Inc. | 4.61% | -2.96% | -0.33% | 2.38% | 10.81% | 21.68% | 28.77% | 32.79% | 32.14% | 33.61% | 30.29% | 28.47% | 26.28% | 18.86% | 16.23% | 15.21% | 12.22% | 22.05% | 24.21% | 25.77% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 15.87% | 15.32% | 14.29% | 15.22% | 16.03% | 17.90% | 17.80% | 19.14% | 25.05% | 27.49% | 39.84% | 43.03% | 40.53% | 41.02% | 33.43% | 31.86% | 31.17% | 32.94% | 18.79% | 19.08% | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 12.52% | 13.12% | 13.26% | 12.83% | 13.11% | 13.08% | 14.26% | 15.80% | 16.15% | 17.59% | 18.56% | 18.94% | 22.13% | 23.32% | 22.60% | 18.47% | 15.33% | 12.41% | 12.85% | 12.45% | — | — | — | |||||||
Basado en los informes: 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31), 10-K (Fecha del informe: 2019-12-31), 10-Q (Fecha del informe: 2019-09-30), 10-Q (Fecha del informe: 2019-06-30), 10-Q (Fecha del informe: 2019-03-31).
1 Q3 2024 cálculo
ROE = 100
× (Utilidad (pérdida) netaQ3 2024
+ Utilidad (pérdida) netaQ2 2024
+ Utilidad (pérdida) netaQ1 2024
+ Utilidad (pérdida) netaQ4 2023)
÷ Capital social total de Eli Lilly and Company
= 100 × (970,300 + 2,967,000 + 2,242,900 + 2,189,700)
÷ 14,240,000 = 58.78%
2 Haga clic en el nombre del competidor para ver los cálculos.
| Ratio de rentabilidad | Descripción | La empresa |
|---|---|---|
| ROE | Ratio de rentabilidad calculado como el beneficio neto dividido por el patrimonio neto. | El ratio de rentabilidad sobre el capital contable de Eli Lilly & Co. mejorado del 1T 2024 al 2T 2024 y del 2T 2024 al 3T 2024. |
Ratio de rentabilidad sobre activos (ROA)
Eli Lilly & Co., ROA, cálculo (datos trimestrales)
| 30 sept. 2024 | 30 jun. 2024 | 31 mar. 2024 | 31 dic. 2023 | 30 sept. 2023 | 30 jun. 2023 | 31 mar. 2023 | 31 dic. 2022 | 30 sept. 2022 | 30 jun. 2022 | 31 mar. 2022 | 31 dic. 2021 | 30 sept. 2021 | 30 jun. 2021 | 31 mar. 2021 | 31 dic. 2020 | 30 sept. 2020 | 30 jun. 2020 | 31 mar. 2020 | 31 dic. 2019 | 30 sept. 2019 | 30 jun. 2019 | 31 mar. 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Datos financieros seleccionados (US$ en miles) | ||||||||||||||||||||||||||||||
| Utilidad (pérdida) neta | 970,300) | 2,967,000) | 2,242,900) | 2,189,700) | (57,400) | 1,763,200) | 1,344,900) | 1,937,700) | 1,451,700) | 952,500) | 1,902,900) | 1,726,100) | 1,110,100) | 1,390,200) | 1,355,300) | 2,116,800) | 1,208,400) | 1,412,000) | 1,456,500) | 1,495,700) | 1,253,900) | 1,327,200) | 4,241,600) | |||||||
| Activos totales | 75,606,900) | 71,874,800) | 63,943,500) | 64,006,300) | 57,915,500) | 54,814,000) | 53,163,000) | 49,489,800) | 47,461,500) | 47,063,600) | 46,919,300) | 48,806,000) | 48,187,000) | 47,809,000) | 46,838,300) | 46,633,100) | 43,946,000) | 41,967,000) | 41,102,800) | 39,286,100) | 37,893,100) | 38,666,400) | 38,006,800) | |||||||
| Ratio de rentabilidad | ||||||||||||||||||||||||||||||
| ROA1 | 11.07% | 10.22% | 9.60% | 8.19% | 8.61% | 11.85% | 10.70% | 12.62% | 12.71% | 12.09% | 13.06% | 11.44% | 12.39% | 12.70% | 13.01% | 13.28% | 12.68% | 13.39% | 13.46% | 21.17% | — | — | — | |||||||
| Referencia | ||||||||||||||||||||||||||||||
| ROACompetidores2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 3.57% | 3.76% | 4.03% | 3.61% | 4.78% | 6.42% | 5.64% | 8.53% | 9.49% | 8.83% | 8.71% | 7.88% | 5.06% | 4.50% | 3.43% | 3.07% | 4.93% | 4.65% | 9.25% | 8.84% | — | — | — | |||||||
| Amgen Inc. | 4.65% | 3.44% | 4.05% | 6.91% | 8.36% | 8.84% | 8.92% | 10.06% | 10.73% | 11.09% | 9.67% | 9.63% | 8.63% | 9.61% | 11.33% | 11.54% | 11.37% | 11.23% | 12.45% | 13.13% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -7.75% | -6.91% | -6.21% | 8.43% | 9.08% | 8.52% | 7.75% | 6.53% | 6.80% | 6.59% | 6.07% | 6.40% | -4.87% | -4.58% | -5.53% | -7.61% | -0.04% | -0.44% | 0.74% | 2.65% | — | — | — | |||||||
| Danaher Corp. | 4.83% | 5.35% | 5.28% | 5.64% | 6.74% | 7.49% | 8.15% | 8.55% | 8.35% | 7.76% | 7.74% | 7.73% | 7.13% | 7.19% | 6.30% | 4.79% | 5.05% | 4.86% | 4.74% | 4.85% | — | — | — | |||||||
| Gilead Sciences Inc. | 0.23% | 1.97% | 0.86% | 9.12% | 9.42% | 8.80% | 9.02% | 7.27% | 5.33% | 6.58% | 7.16% | 9.16% | 11.02% | 7.59% | 0.45% | 0.18% | 2.08% | -0.46% | 8.31% | 8.74% | — | — | — | |||||||
| Johnson & Johnson | 8.24% | 20.99% | 22.37% | 20.98% | 20.85% | 6.81% | 6.49% | 9.57% | 10.94% | 10.33% | 11.12% | 11.47% | 9.98% | 10.07% | 8.76% | 8.41% | 9.95% | 9.59% | 11.07% | 9.59% | — | — | — | |||||||
| Merck & Co. Inc. | 10.34% | 12.20% | 2.18% | 0.34% | 4.32% | 2.98% | 12.09% | 13.30% | 14.25% | 15.48% | 13.29% | 12.35% | 7.70% | 6.14% | 7.73% | 7.72% | 12.83% | 11.56% | 11.95% | 11.66% | — | — | — | |||||||
| Moderna Inc. | -14.07% | -37.42% | -35.67% | -25.58% | -17.82% | 5.52% | 19.83% | 32.34% | 45.15% | 53.97% | 53.02% | 49.46% | 33.75% | 21.64% | 4.71% | -10.18% | -12.85% | -13.98% | -24.46% | -32.34% | — | — | — | |||||||
| Pfizer Inc. | 1.94% | -1.20% | -0.14% | 0.94% | 4.87% | 9.75% | 14.85% | 15.91% | 15.32% | 15.01% | 13.58% | 12.11% | 11.10% | 7.78% | 7.01% | 6.23% | 4.46% | 7.97% | 9.47% | 9.72% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 12.43% | 11.98% | 11.22% | 11.95% | 12.41% | 14.02% | 13.91% | 14.85% | 19.40% | 20.90% | 30.11% | 31.75% | 29.55% | 28.88% | 22.53% | 20.47% | 19.62% | 20.68% | 14.46% | 14.29% | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 6.11% | 6.32% | 6.21% | 6.07% | 6.12% | 6.08% | 6.36% | 7.15% | 7.77% | 8.21% | 8.20% | 8.12% | 11.64% | 12.70% | 12.02% | 9.23% | 7.62% | 6.02% | 6.25% | 6.33% | — | — | — | |||||||
Basado en los informes: 10-Q (Fecha del informe: 2024-09-30), 10-Q (Fecha del informe: 2024-06-30), 10-Q (Fecha del informe: 2024-03-31), 10-K (Fecha del informe: 2023-12-31), 10-Q (Fecha del informe: 2023-09-30), 10-Q (Fecha del informe: 2023-06-30), 10-Q (Fecha del informe: 2023-03-31), 10-K (Fecha del informe: 2022-12-31), 10-Q (Fecha del informe: 2022-09-30), 10-Q (Fecha del informe: 2022-06-30), 10-Q (Fecha del informe: 2022-03-31), 10-K (Fecha del informe: 2021-12-31), 10-Q (Fecha del informe: 2021-09-30), 10-Q (Fecha del informe: 2021-06-30), 10-Q (Fecha del informe: 2021-03-31), 10-K (Fecha del informe: 2020-12-31), 10-Q (Fecha del informe: 2020-09-30), 10-Q (Fecha del informe: 2020-06-30), 10-Q (Fecha del informe: 2020-03-31), 10-K (Fecha del informe: 2019-12-31), 10-Q (Fecha del informe: 2019-09-30), 10-Q (Fecha del informe: 2019-06-30), 10-Q (Fecha del informe: 2019-03-31).
1 Q3 2024 cálculo
ROA = 100
× (Utilidad (pérdida) netaQ3 2024
+ Utilidad (pérdida) netaQ2 2024
+ Utilidad (pérdida) netaQ1 2024
+ Utilidad (pérdida) netaQ4 2023)
÷ Activos totales
= 100 × (970,300 + 2,967,000 + 2,242,900 + 2,189,700)
÷ 75,606,900 = 11.07%
2 Haga clic en el nombre del competidor para ver los cálculos.
| Ratio de rentabilidad | Descripción | La empresa |
|---|---|---|
| ROA | Ratio de rentabilidad calculado como el ingreso neto dividido por los activos totales. | El ratio de rentabilidad sobre activos de Eli Lilly & Co. mejorado del 1T 2024 al Q2 2024 y del Q2 2024 al Q3 2024. |